A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Impaired digestion, especially after eating.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.
Slow or difficult OBSTETRIC LABOR or CHILDBIRTH.
Tumors or cancer of the APPENDIX.
A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)
Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.
Distention of KIDNEY with the presence of PUS and suppurative destruction of the renal parenchyma. It is often associated with renal obstruction and can lead to total or nearly total loss of renal function.
A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
The reaction of potassium ferrocyanide with ferric iron to yield a dark blue precipitate at the sites of the ferric iron. Used to determine ferric iron in tissues, particularly in the diagnosis of disorders of iron metabolism.
A benign neoplasm of the ovary.
Tumors or cancer of the PAROTID GLAND.
A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
Tumors or cancer of the BILE DUCTS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors or cancer of the SALIVARY GLANDS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Organic compounds containing both the hydroxyl and carboxyl radicals.
The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Proteins secreted by the epididymal epithelium. These proteins are both tissue- and species-specific. They are important molecular agents in the process of sperm maturation.
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
Loss of structural differentiation and useful function of neoplastic cells.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
Tumors or cancer of the PERITONEUM.
A pair of highly specialized muscular canals extending from the UTERUS to its corresponding OVARY. They provide the means for OVUM collection, and the site for the final maturation of gametes and FERTILIZATION. The fallopian tube consists of an interstitium, an isthmus, an ampulla, an infundibulum, and fimbriae. Its wall consists of three histologic layers: serous, muscular, and an internal mucosal layer lined with both ciliated and secretory cells.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
An organoplatinum compound that possesses antineoplastic activity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Theory and development of COMPUTER SYSTEMS which perform tasks that normally require human intelligence. Such tasks may include speech recognition, LEARNING; VISUAL PERCEPTION; MATHEMATICAL COMPUTING; reasoning, PROBLEM SOLVING, DECISION-MAKING, and translation of language.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
A publication issued at stated, more or less regular, intervals.
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
The premier bibliographic database of the NATIONAL LIBRARY OF MEDICINE. MEDLINE® (MEDLARS Online) is the primary subset of PUBMED and can be searched on NLM's Web site in PubMed or the NLM Gateway. MEDLINE references are indexed with MEDICAL SUBJECT HEADINGS (MeSH).
Publications in any medium issued in successive parts bearing numerical or chronological designations and intended to be continued indefinitely. (ALA Glossary of Library and Information Science, 1983, p203)
All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/526)

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.  (+info)

The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. (2/526)

The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells, especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely unknown. We have investigated the presence of C/EBPalpha, -beta, -delta and -zeta in normal ovaries and in epithelial ovarian tumours of different stages. Immunohistochemical experiments demonstrated that C/EBPalpha and C/EBPbeta were preferentially expressed in epithelial/tumour cells irrespective of stage or grade of the tumour. C/EBPbeta was located in the nuclei of the cells, in contrast to C/EBPalpha, which was present only in the cytoplasm of these cells. The nuclear localization of C/EBPbeta indicates an active role of this transcription factor in tumour cells, whereas the cytoplasmic distribution suggests a more passive function of C/EBPalpha. C/EBPdelta and -zeta demonstrated a more diverse distribution with predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the nucleus and the cytoplasm for C/EBPdelta and -zeta. Western blotting demonstrated that C/EBPalpha, -beta, -delta and -zeta were present in a majority of the samples. The amount of C/EBPbeta increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPbeta as a potential marker for these tumours. As C/EBPbeta is known to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and play a central role in tumour progression.  (+info)

Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (3/526)

Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer.  (+info)

Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. (4/526)

Between 1976 and 1996, 176 borderline ovarian tumours were registered in the Cancer Registry of the Swiss canton of Vaud, corresponding to an age-adjusted incidence (world standard) of 2.7 in 100,000. Incidence rose from 1.7 per 100,000 during 1976-81 to 2.7 per 100,000 during 1987-91, and then levelled off; 58% of cases were serous and 41% mucinous. Relative survival was 94% at 10 years; 18 second neoplasms were observed, compared with 10.3 expected, and there was a significant excess of invasive ovarian cancers (four observed, including three synchronous, compared with 0.4 expected).  (+info)

Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. (5/526)

AIM: To determine whether three-dimensional power Doppler can improve the recognition of pelvic tumor morphology and angiogenesis. METHODS: Using this technique we analyzed 180 adnexal masses and 110 uterine lesions. Tumor volume, morphology, and vascularity were evaluated in each patient. Irregular and randomly dispersed vessels with complex branching depicted by comprehensive three dimensional display were suggestive of pelvic malignancy, while linear-like vascular morphology, single vessel arrangement and regular branching were typical for benign structures. RESULTS: Addition of qualitative analysis of vascular architecture of adnexal tumor to morphological parameters reached 96.15% sensitivity and 98.73% specificity. When endometrial lesions were prospectively analyzed, sensitivity and specificity were 91.67% and 98.49%, respectively. Because the lowest positive predictive value of 16.67% was obtained for myometrial lesions, this method should not be advised for their eva luation. CONCLUSION: Good results achieved by three dimensional ultrasound can be explained by improved recognition of the pelvic lesion anatomy, characterization of the surface features, detection of the tumor infiltration, and precise depiction of the size and volume. Three dimensional power Doppler imaging can detect structural abnormalities of the malignant tumor vessels, such as arteriovenous shunts, microaneurysms, tumoral lakes, disproportional calibration, coiling, and dichotomous branching. Therefore it enhances and facilitates the morphologic and functional evaluation of both benign and malignant pelvic tumors.  (+info)

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/526)

Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not.  (+info)

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. (7/526)

The purpose of this study was to investigate the frequency of p53 overexpression in the primary ovarian tumors of patients with stages II and III serous borderline tumors (SBTs) and to determine the relationship between p53 overexpression and risk of progression/recurrence and survival. Of 112 patients with stages II-IV SBTs, paraffin-embedded tissue from the primary ovarian tumor was available in 68 cases. Immunohistochemical staining for p53 was performed. Clinical information was abstracted from the medical records. The major end points selected for analysis were time to progression/relapse, disease-free survival, overall survival, and cause-specific survival. Univariate and multivariate regression analyses were also performed. The median patient age was 37 years (range, 17-67 years). Twenty-two patients had stage II disease, and 46 had stage III disease. The mean follow-up time was 105 months. Nineteen patients (28%) had either disease progression (1 patient) or relapse (18 patients). Eleven patients died: 10 patients died of their tumor, and 1 patient died of other causes. Thirteen cases (19%) had positive immunostaining for p53. Overexpression of p53 was significantly associated with an increased probability of progression/recurrence (P = 0.005) and a decreased overall survival (P = 0.012). After adjusting for age, International Federation of Gynecology and Obstetrics (FIGO) stage, the presence of residual tumor, and the presence of invasive implants, patients whose tumors overexpressed p53 had a 4-fold increased risk of progression/ recurrence. Similarly, women whose tumor overexpressed p53 had an approximately 6-fold increased risk of death. p53 overexpression in the ovarian tumors of patients with stage II and III SBTs is significantly associated with increased probability of relapse and decreased overall survival. This information should provide better prognostic data to patients and their families and allow us to select patients who might benefit from postoperative treatment.  (+info)

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. (8/526)

Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.  (+info)

GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 Jan 11;:109539 Authors: El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G Abstract High-grade serous ovarian carcinoma (HGSOC) is the mos...
There are 5 clinical trials for malignant ovarian serous tumor, of which 5 are open and 0 are completed or closed. Of the trials that contain malignant ovarian serous tumor as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open). BRCA1 and BRCA2 are the most frequent gene inclusion criteria for malignant ovarian serous tumor clinical trials [3]. ...
The TP53 gene mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%. A research team working at the The Sidney Kimmel Comprehensive Cancer Center of The Johns Hopkins Medical Institutions (Johns Hopkins) made several important findings regarding TP53 gene mutations with respect to high grade ovarian serous carcinoma, as reported in the International Journal of Gynecological Cancer. Ovarian serous carcinoma is the most common tumor subtype within the epithelial ovarian cancer histological classification.. According to the Johns Hopkins research team, a stringent analysis of the TP53 gene using purified epithelial tumor samples has not been performed to accurately assess the TP53 gene mutation frequency and its correlation to tumor histologic grade. The research team assessed the TP53 gene mutational profile in a relatively large series of high-grade (53 primary tumors and 18 recurrent tumors) and 13 low-grade ovarian serous tumors. All samples were ...
TY - JOUR. T1 - Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. AU - Espinosa, Inigo. AU - Catasus, Lluis. AU - Canet, Belén. AU - DAngelo, Emanuela. AU - Mũoz, Josefina. AU - Prat, Jaime. PY - 2011/6/1. Y1 - 2011/6/1. N2 - Gene expression profiling is an important tool to evaluate genetic heterogeneity in carcinomas and is useful to develop expression-based classifications for many types of cancer, as well as markers of disease outcome. In this study, we have investigated the expression profile of 22 genes involved in the PI3K-AKT pathway in 26 high-grade ovarian carcinomas (19 serous and 7 clear cell carcinomas). Unsupervised hierarchical clustering divided high-grade ovarian carcinomas into three groups. Although all clear cell carcinomas clustered in one group, high-grade serous carcinomas were segregated into two separate groups with different prognosis (P=0.05). High expression of CASP3, XIAP (X-linked inhibitor of ...
The TP53 mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%, but a stringent analysis of TP53 using purified epithelial samples has not yet been performed to accurately assess the mutation frequency and to correlate it with the histologic grade. The purpose of this study was to assess the TP53 mutational profile in a relatively large series of high-grade (53 primary and 18 recurrent) and 13 low-grade ovarian serous tumors using DNA isolated from affinity-purified tumor cells and to correlate it with in vitro drug resistance. All samples were affinity purified, and the tumor DNA was analyzed for TP53 mutations in exons 4-9. In vitro drug resistance assays to carboplatin, cisplatin, paclitaxel, and taxotere were performed on the same tumor samples and correlated with the TP53 mutation status. TP53 mutations were detected in 57 (80.3%) of 71 high-grade carcinomas and in one (7.8%) of 13 low-grade serous tumors (an invasive low-grade serous carcinoma). The ...
Dishevelled family proteins (DVL1, DVL2 and DVL3) are cytoplasmic mediators involved in canonical and non-canonical Wnt signaling that are important for embryonic development. Since Wnt signaling promotes cell proliferation and invasion, its increased activation is associated with cancer development as well. To get deeper insight into the behavior of Dishevelled proteins in cancer, we studied their expression in serous ovarian carcinomas [both low- (LGSC) and high-grade (HGSC)], and HGSC cell lines OVCAR5, OVCAR8 and OVSAHO. DVL protein expression in serous ovarian carcinomas tissues was analyzed using immunohistochemistry while DVL protein and mRNA expressions in HGSC cell lines were analyzed using western blot and quantitative real-time PCR. DVL1 protein expression was significantly higher in LGSC compared with normal ovarian tissue, while DVL3 was overexpressed in both LGSC and HGSC. DVL2 and DVL3 protein expression was higher in HGSC cell lines when compared with normal control cell line ...
Uterine serous carcinoma is a rare and highly aggressive variant of endometrial cancer. Uterine serous carcinoma accounts for 10% of all endometrial cancer; however, it carries the poorest prognosis, with 5-year survival rates as low as 55%. Whole-exome sequencing studies have recently reported c-Myc gene amplification in a large ...
NAD(P)H:quinone oxidoreductase (NQO1) is a flavoprotein that catalyzes two-electron reduction and detoxification of quinones and its derivatives. NQO1 catalyzes reactions that have a protective effect against redox cycling, oxidative stress and neoplasia. High expression of NQO1 is associated with many solid tumors including those affecting the colon, breast and pancreas; however, its role in the progression of ovarian carcinoma is largely undefined. This study aimed to investigate the clinicopathological significance of high NQO1 expression in serous ovarian carcinoma. NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect NQO1 mRNA expression levels. The correlation between high NQO1 expression and clinicopathological features of ovarian carcinoma was evaluated by
High-grade serous ovarian cancer (HGSOC) is the most aggressive histological type of epithelial ovarian cancer, which is characterized by a high frequency of somatic TP53 mutations. We performed exome analyses of tumors and matched normal tissues of 34 Japanese patients with HGSOC and observed a substantial number of patients without TP53 mutation (24%, 8/34). Combined with the results of copy number variation analyses, we subdivided the 34 patients with HGSOC into subtypes designated ST1 and ST2. ST1 showed intact p53 pathway and was characterized by fewer somatic mutations and copy number alterations. In contrast, the p53 pathway was impaired in ST2, which is characterized by abundant somatic mutations and copy number alterations. Gene expression profiles combined with analyses using the Gene Ontology resource indicate the involvement of specific biological processes (mitosis and DNA helicase) that are relevant to genomic stability and cancer etiology. In particular we demonstrate the presence of a
High-grade serous ovarian cancer (HGSOC) likely originates from the fallopian tube (FT) epithelium, but advanced stages are mostly found outside the FT. We used ex-vivo cultures of HGSOC and knock-out of tumor suppressors in FT organoids to study changes in epithelial cells and niche requirements for normal and transformed FT cells. We found that transformed cells require BMP signaling and are growth arrested in Wnt rich medium. A SureSelectXT Automation Custom Capture Library (Agilent) target enrichment panel was designed. The enrichment panel comprised all coding exons of 121 genes associated with ovarian cancer. Capture was performed according to the manufacturers instructions using an NGS Workstation Option B (Agilent) for automat... (Read more) ...
The effective treatment of ovarian serous carcinoma remains a major challenge because of the recurrence of platinum-resistant tumors. The mechanism of platinum-resistance may involve decreased cellular uptake caused by abnormalities of transporters, intracellular cisplatin inactivation (e.g., caused by glutathione), and increased DNA repair (18). However, no available therapy prevents platinum-resistance.. TBX2 is overexpressed by numerous human cancers (7-14). TBX2 may serve as a prognostic factor of breast cancer (7,9), melanoma (8), gastric cancer (10), prostate cancer (11), laryngeal squamous cell carcinoma (12), and non-small cell lung cancer (14). TBX2 is associated with resistance to therapeutic drugs such as cisplatin and doxorubicin (15,16), and TBX2 therefore may serve as a therapeutic target.. One report shows that chromosome 17q12-q24 harbors strong candidates for ovarian tumorigenesis, such as LASP1 (17q12), TGF11 (17q21.32), MUL (17q23.2), TBX2 (17q23.2), AXIN2 (17q24.3), and GRB2 ...
Dr. Natalie Banet moderates the discussion of studies pertinent to the practice of Gynecological Pathology, led by pathology trainees. Articles to be covered: Zarei S, et al. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. Am J Surg Pathol. 2020;44(3):316-328. Seidman JD, et al. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary…. ...
High-grade serous ovarian carcinoma (HGSOC) is a lethal disease for which improved screening and treatment strategies are urgently required. Progress in these areas has been impeded by our poor understanding of HGSOC pathogenesis. The vast majority of ovarian cancer research is been based on the hypothesis that HGSOC develops from ovarian surface epithelial cells. However, recent studies suggest that , 50% of high-grade serous carcinomas involving the ovary likely arose from secretory cells of the fallopian tube epithelium. Consequently, current ovarian-based experimental models of HGSOC are inadequate in representing the full spectrum of the disease. The aim of our study was to develop the first experimental model of fallopian tube secretory epithelial cell (FTSEC) transformation and to use this model to answer three basic questions: 1) Can FTSECs be transformed in vitro?, 2) What genetic alterations are capable of transforming FTSECs?, and 3) Do transformed FTSECs give rise to high-grade ...
Ovarian cancer accounts for 5% of all female cancer-related deaths, more than any other reproductive cancer. Of the various histological subtypes, high-grade serous carcinoma is the most common. Mutations in BRCA1/BRCA2, which are associated with familial predisposition, are present in 10% of cases, while TCGA data demonstrates that P53 is mutated in 96% of high-grade serous ovarian carcinomas. In addition to aberrant P53 expression, severe aneuploidy with a near polyploid number of chromosomes is the only other genetic abnormality associated with these tumors. Ploidy changes occur early in tumor development, suggesting that they play a crucial role in oncogenic transformation. Furthermore, severe aneuploidy is associated with poor clinical outcome in patients, presumably due to its role in treatment resistance.. We used an in vitro cell culture model derived from ovarian cystadenomas, the benign counterparts of ovarian carcinomas, to investigate the molecular events leading to such ploidy ...
Objective: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in patients with stage III ovarian high-grade serous carcinoma (HGSC). Methods: A multicenter, retrospective department database review was performed to identify patients with ovarian HGSC at 6 gynecologic oncology centers in Turkey. A total of 229 node-positive women with stage III ovarian HGSC who had undergone maximal or optimal cytoreductive surgery plus systematic lymphadenectomy followed by paclitaxel plus carboplatin combination chemotherapy were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 3 groups: LNR1 (,10%), LNR2 (10%,= LNR,50%), and LNR3 (,= 50%). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models. Results: Thirty-one women (13.6%) were classified as stage IIIA1, 15 (6.6%) as stage IIIB, and 183 (79.9%) as stage IIIC. The ...
This review focuses on recent advances in the area of low-grade ovarian serous neoplasia with emphasis on key diagnostic criteria, differential diagnosis, and disease classification based on current understanding of low-grade serous carcinogenesis. Despite considerable controversy surrounding serous tumors of low malignant potential (S-LMP) or borderline tumors, there have been great strides in our understanding of the serous group of borderline and malignant pelvic epithelial neoplasms in the past decade. Most S-LMP have a favorable prognosis, but recurrences and progression to carcinoma occur, sometimes following a protracted clinical course. Pathologic risk factors vary, but the extraovarian implant status is the most important predictor for progressive disease. Progression of S-LMP usually takes the form of low-grade serous carcinoma, although transformation to high-grade carcinoma is occasionally seen. A pelvic S-LMP - low-grade serous carcinoma pathway has been proposed based on global gene
Study identifies cell-of-origin in the development of many ovarian tumors, including including high grade serous ovarian carcinoma (HGSOC)
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
See also ; ovarian tumors Appearance : ovarian epithelial tumors ovarian serous tumors benign ovarian serous tumors proliferating (...)
Mutations in the gene encoding the p110α subunit of PI3K (PIK3CA) that result in enhanced PI3K activity are frequently observed in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis, we generated mice in which a PIK3CA mutation commonly detected in human cancers (the H1047R mutation) could be conditionally knocked into the endogenous Pik3ca locus. Activation of this mutation in the mouse ovary revealed that alone, Pik3caH1047R induced premalignant hyperplasia of the ovarian surface epithelium but no tumors. Concomitantly, we analyzed several human ovarian cancers and found PIK3CA mutations coexistent with KRAS and/or PTEN mutations, raising the possibility that a secondary defect in a co-regulator of PI3K activity may be required for mutant PIK3CA to promote transformation. Consistent with this notion, we found that Pik3caH1047R mutation plus Pten deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and ...
Complex focal chromosomal rearrangements in cancer genomes, also called firestorms, can be scored from DNA copy number data. The complex arm-wise aberration index (CAAI) is a score that captures DNA copy number alterations that appear as focal complex events in tumors, and has potential prognostic value in breast cancer. This study aimed to validate this DNA-based prognostic index in breast cancer and test for the first time its potential prognostic value in ovarian cancer. Copy number alteration (CNA) data from 1950 breast carcinomas (METABRIC cohort) and 508 high-grade serous ovarian carcinomas (TCGA dataset) were analyzed. Cases were classified as CAAI positive if at least one complex focal event was scored. Complex alterations were frequently localized on chromosome 8p (n = 159), 17q (n = 176) and 11q (n = 251). CAAI events on 11q were most frequent in estrogen receptor positive (ER+) cases and on 17q in estrogen receptor negative (ER-) cases. We found only a modest correlation between ...
Low grade serous ovarian cancer affects approximately 1 in 1000 women, many will be diagnosed in their 20s and 30s. With current medical treatments ...
Ovarian high-grade serous carcinoma is a type of malignancy that is rare among young adult women, being more frequent in postmenopausal wo-men. Cancer of the ovary, fallopian tube and peritoneum. Lymph Node Dissection for Ovarian Cancer gastric cancer research Leacuri detoxifiere ficat verruca foot sock, hpv e cancer de pulmao cancer femei simptome.
https://doi.org/10.18632/oncotarget.21175 Véronique DHondt, Magalie Lacroix-Triki, Marta Jarlier, Florence Boissiere-Michot, Carole Puech, Peter Coopman, Dionyssios Katsaros, Gilles Freiss
The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were va …
David Bowtell, Steffen Böhm, Ahmed Ahmed, Paul-Joseph Aspuria, Robert C Bast, Jr, Valerie Beral, Jonathan S Berek, Mike Birrer, Sarah Blagden, Michael A Bookman, James Brenton, Katherine B Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas A Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad H Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil K Sood, Euan A Stronach, Frances Balkwill: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015 ...
David Bowtell, Steffen Böhm, Ahmed Ahmed, Paul-Joseph Aspuria, Robert C Bast, Jr, Valerie Beral, Jonathan S Berek, Mike Birrer, Sarah Blagden, Michael A Bookman, James Brenton, Katherine B Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas A Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad H Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil K Sood, Euan A Stronach, Frances Balkwill: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015 ...
Purpose: In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and the CD8+ T cell infiltrate were associated with a better prognosis. However, the precise role of B cells in the anti-tumor response remains unknown. As peritoneal metastases are often responsible for relapse, our aim was to characterize the role of B cells in the anti-tumor immune response in HGSOC metastases. Experimental Design: Unmatched pre and post-chemotherapy HGSOC metastases were studied. B-cell localization was assessed by immunostaining. Their cytokines and chemokines were measured by multiplex assay and their phenotype was assessed by flow cytometry. Further in vitro and in vivo assays highlighted the role of B cells and plasma cell IgGs in the development of cytotoxic responses and dendritic cell activation. Results: B cells mainly infiltrated lymphoid structures in the stroma of HGSOC metastases. There was a strong B-cell memory response directed at a restricted repertoire of antigens and ...
PMID: 26867183, PMCID: PMC5271177. Integrated proteogenomic characterization of human high-grade serous ovarian cancer, H. Zhang, T. Liu, Z. Zhang, S. H. Payne, B. Zhang, J. E. McDermott, J. Y. Zhou, V. A. Petyuk. L. Chen, D. Ray, S. Sun, F. Yang, L. Chen, J. Wang, P. Shah, S. W. Cha, P. Aiyetan, S. Woo, Y. Tian, M. A. Gritsenko, T. R. Clauss, C. Choi, M. E. Monroe, S. Thomas, S. Nie, C. Wu, R. J. Moore, K. H. Yu, D. L. Tabb, D. Fenyo, V. Bafna, Y. Wang, H. Rodriguez, E. S. Boja, T. Hiltke, R. C. Rivers, L. Sokoll, H. Zhu, IeM. Shih, L. Cope, A. Pandey, B. Zhang, M. P. Snyder, D. A. Levine, R. D. Smith, D. W. Chan, K. D. Rodland, and CPTAC Investigators, Cell 166 (3): 755-765 (2016 ...
TY - JOUR. T1 - Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum. AU - Hinson, Stacy A.. AU - Silva, Elvio G.. AU - Pinto, K.. PY - 2013/6/1. Y1 - 2013/6/1. N2 - Ovarian serous cystadenofibromas are benign neoplasms that sometimes have focal areas of borderline serous tumor and rarely have been associated with epithelial proliferations in the peritoneum, resembling implants. We are reporting 2 cases of ovarian serous cystadenofibromas with serous peritoneal lesions of higher grade than the ovarian tumor: 1 case had a serous carcinoma and another 1 a serous borderline tumor.. AB - Ovarian serous cystadenofibromas are benign neoplasms that sometimes have focal areas of borderline serous tumor and rarely have been associated with epithelial proliferations in the peritoneum, resembling implants. We are reporting 2 cases of ovarian serous cystadenofibromas with serous peritoneal lesions of higher grade than the ovarian tumor: 1 case had a serous ...
Uterine papillary serous carcinoma (UPSC) is an uncommon, but aggressive variant of endometrial carcinoma that has a high recurrence rate and poor response to therapy. It has a propensity to metastasize throughout the abdomen, similar to serous carcinoma of the ovary. In fact, many patients with disease apparently confined to the uterus have microscopic intra-abdominal spread at the time of diagnosis. Recurrences are common both in the pelvis as well as in the upper abdomen.. After staging and debulking of gross disease, adjuvant radiation therapy is recommended to treat patients with endometrial carcinoma at high risk for recurrent disease. High-risk features include histologic cell type, grade, depth of myometrial invasion, cervical extension, lymph-vascular invasion, adnexal involvement, intraperitoneal spread, positive peritoneal cytology, and positive lymph nodes. Pelvic radiation can limit local recurrences to less than 6.5%. However, approximately 25-30% of patients with high-risk ...
TY - JOUR. T1 - Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. AU - Ayeni, Tina A.. AU - Bakkum-Gamez, Jamie N. AU - Mariani, Andrea. AU - McGree, Michaela E.. AU - Weaver, Amy L.. AU - Alhilli, Mariam M.. AU - Martin, Janice R.. AU - Keeney, Gary. AU - Dowdy, Sean Christopher. AU - Podratz, Karl C.. PY - 2013/1. Y1 - 2013/1. N2 - Objective: Abdominal peritoneal implants are characteristic of uterine serous carcinoma (USC). The presumed mechanism of dissemination is retrograde transit via the fallopian tube. We assessed the impact of tubal ligation (TL) on the metastatic profile and survival of USC patients. Methods: Patient risk factors, process-of-care variables, and disease-specific parameters were annotated. Categorical variables were compared using the χ2 test. Overall survival (OS) was estimated via the Kaplan-Meier method. Results: Among 211 USC patients, fallopian tube status was documented in 142 patients; 35 had a history of TL ...
Objectives: To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT) +/- radiotherapy (RT). Methods: A retrospective, multi-institution study of women with stage II UPSC diagnosed from 1992 to 2006 was performed. All patients underwent comprehensive surgical staging. Treatment included observation (OBS), RT (vaginal brachytherapy, whole pelvic and/or whole abdominal therapy), or ≥ 3 cycles carboplatin/paclitaxel alone or with RT. Recurrence and survival outcomes were determined. Results: We identified 55 subjects: 10 treated with OBS, 26 with RT alone and 19 with CT +/- RT. After a median follow-up of 33 mos (range, 10-119), 20 recurrences (36%) were observed. There was an overall difference in recurrence based upon treatment (p = .013). Specifically, all CT +/- RT treated patients had a lower risk of recurrence (11%) compared to patients ...
Xu, J., et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. The International Journal of Biochemistry & Cell Biology. S1357-2725(18)30258-9. 10/12/2018.. We identified 634 differentially expressed peptides, 508 of these peptides were highly abundant in serous ovarian cancer tissues, a result consistent with higher protease activity in ovarian cancer patients. The difference in preferred cleavage sites between the serous ovarian cancer tissues and normal ovarian epithelium indicates the characteristic peptidome of ovarian cancer and the nature of cancer-associated protease activity. Interestingly, KEGG pathway analysis of the peptide precursors indicated that the differentially regulated pathways in ovarian cancer are highly consistent with the pathways discovered in other cancers. Besides, we found that a proportion of the differentially expressed peptides are similar to the known immune-regulatory peptides and anti-bacterial peptides. Then we further ...
Uterine papillary serous carcinoma: A rare type of endometrial carcinoma with worse outcomes-IJOGR-Print ISSN No:-2394-2746 Online ISSN No:-2394-2754Article DOI No:-10.18231/2394-2754.2019.0022,Indian Journal of Obstetrics and Gynecology Research-IP Innovative Publication Pvt Limited, Medical Journals Publication, Op
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.
Researchers used Caris Molecular Intelligence® to evaluate 240 uterine papillary serous carcinoma (UPSC) and 1,587 epithelial ovarian serous carcinoma (EOC-S) samples, and to compare the molecular profiles of the two cancer subtypes.. The tumor suppressor gene TP53 was the most commonly mutated gene in both UPSC and EOC-S (76% vs. 69%) samples. UPSCs were more likely than EOC-S samples to harbor mutations in the oncogenes PIK3CA (29% vs. 2%), FBXW7 (12% vs. 1%), KRAS (9% vs. 5%), the tumor suppressor protein PTEN (7% vs. 1%), and CTNNB1 (2% vs. 0%).. Whereas uterine papillary serous carcinoma appears to have a distinct mutation profile, indicating higher activity of the PI3K/PTEN/mTOR pathway, we saw no differences between uterine papillary and ovarian serous carcinomas in alteration of the homologous recombination pathway, remarked principal investigator Robert DeBernardo, MD, Gynecologic Oncologist and Director of Minimally Invasive Surgery at the Cleveland Clinic Ob/Gyn & Womens Health ...
In this study a new low-grade serous ovarian carcinoma cell line, named as CAISMOV24, was characterized in terms of its in vitro cell growth, production of soluble biomarkers and expression of cell surface molecules. Additionally, CAISMOV24 was molecularly characterized and compared to its primary malignant cells for genomic alterations. In vitro models of well-characterized low-grade serous ovarian cell lines are currently limited in the literature. CAISMOV24 resulted from the in vitro spontaneous immortalization of primary malignant cells from ascites that was associated with a low-grade serous ovarian carcinoma. Although malignant cells of ovarian neoplasia from either tumor tissue or ascites can be cultivated in vitro for a limited period, only a minority of the primary cell cultures may become cell lines [14]. Spontaneous immortalization of primary cultures of malignant cells is an event occurring at a very low frequency. As an example, ODonnell et al. [11] reported the occurrence of only ...
TY - JOUR. T1 - Is invasive micropapillary serous carcinoma a low-grade carcinoma?. AU - Ohishi, Yoshihiro. AU - Imamura, Hiroko. AU - Aman, Murasaki. AU - Shida, Kaai. AU - Kaku, Tsunehisa. AU - Kato, Kiyoko. AU - Oda, Yoshinao. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Invasive micropapillary serous carcinoma has been proposed as a synonym for low-grade serous carcinoma by some expert pathologists. In contrast, Singer and colleagues reported that some serous carcinomas with conspicuous invasive micropapillary pattern (SC-IMPs) can show high-grade nuclear atypia. However, the molecular features of such tumors have not been well documented. The aim of this study was to demonstrate and emphasize the fact that high-grade serous carcinoma confirmed by immunohistochemistry and molecular analysis can show conspicuous invasive micropapillary pattern. We selected 24 SC-IMPs and investigated: (1) their morphologic features; (2) the immunostaining pattern of p53 protein; and (3) KRAS/BRAF/TP53 gene ...
Serous borderline tumor (SBT) of the micropapillary type (SBT-MP) became one of the major pathological SBT diagnoses in addition to typical SBT, and was also defined as
Epithelial ovarian cancer is a leading cause of death in gynecological cancers. While several systematic studies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as extensively. Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and three mucinous) and their corresponding normal DNA as well as a tumor-only granulosa cell sample. We integrated the exome data with targeted gene sequencing for 1,321 genes selected for their involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial carcinomas ...
I guess my hamster days steroid high is over, because I slept 10 hours last night and woke up with something similar to what Marge described, a sort of fogginess. Its not bad, but I feel like if I crawled back under the covers, I just might go back to sleep again. (Not doing that!) I agree that we are all doing so much better than any of us probably dared to hope. There are surely some rough days ahead, but one day at a time is the way to go, and making the most of each good day. I wonder if we will continue to come here after our treatments are over??? I see 20-year survivors posting here on other boards, wanting to be here as a resource to those that come after them with their same cancers. Id like to think well be like that, with this thread always flagged for email alerts, ready to jump back in when those newly diagnosed with UPSC using the SEARCH box, find this thread. Even if any of us decide to close the door on this chapter of our life and never look back, think how great it will ...
Zanotti The Cleveland Clinic Foundation Uterine papillary serous carcinoma (UPSC) is undoubtedly an intense malignancy which has a histologic visual appeal and pattern of spread that resembles that of papillary serous adenocarcinoma with the ovary. The current conventional therapy for Superior ovarian most cancers, cisplatin or carboplatin moreover paclitaxel, results in high aim response premiums for that tumor. This program has Up to now not been evaluated in i thought about this UPSC. Approaches: 20-four sufferers with UPSC treated with platinum-based mostly chemotherapy and paclitaxel were being retrospectively evaluated. Eighteen clients acquired these agents within the adjuvant placing (n = 9) or for sickness persistent just after initial surgical management (n = nine). Eleven patients gained one or more classes of this drug blend for recurrent ailment, 5 of whom experienced prior publicity while in the First setting ...
Mutations in BRCA1 or BRCA2 (BRCA) are common in patients with high-grade serous ovarian carcinomas, and, when the wild-type allele is lost, BRCA mutations can impair DNA-damage repair by homologous recombination, leading to deletion or duplication of chromosomal regions, which is termed genomic loss of heterozygosity (LOH). Homologous recombination-deficient tumors are sensitive to PARP inhibitors such as rucaparib, but although homologous recombination deficiencies can also occur in ovarian tumors without BRCA mutations, molecular predictors of rucaparib sensitivity in BRCA wild-type tumors have not been identified. Swisher, Lin, and colleagues hypothesized that genomic LOH might predict homologous recombination deficiency and rucaparib sensitivity and enrolled 206 patients in an open-label phase II trial of rucaparib in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma. In total, 192 patients could be classified into subgroups: 40 had BRCA mutations, 82 were BRCA ...
Ueda SM, Yap, KL, Davidson, B et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncology 2010;2010:285191.. Krill LS, Ueda SM, Gerardi M, Bristow RE. Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Article in press for Gynecol Oncol. 2011 Feb; 120(2):220-3. Skaznik-Wikiel ME, Ueda SM, Frasure HE, Rose PG, Fleury A, Grumbine FC, Nickles-Fader A. Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? Acta Cytol 2001;55(3):255-60.. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011;122(2):319-23.. Giuntoli RL, Gerardi ...
Cancer cell lines have been, and will continue to be, important tools in oncology research, but there are major limitations in the fidelity of existing cell lines as a model of human cancers. Therefore, the aim of our study was to generate and characterize patient-specific cell lines from solid tumors that more faithfully recapitulate the primary tumor genetic and morphologic characteristics.. We performed cell line derivation on a primary human breast adenocarcinoma (ER+/PR+/HER2-), a lung adenocarcinoma, a high-grade serous ovarian carcinoma, and an endometrioid ovarian carcinoma procured from a commercial tissue bank. Portions were snap-frozen for molecular analysis, and the remainder was minced and processed for cell culture. Cells were cultured and the resulting monolayer was stained by immunocytochemistry with a pan-keratin antibody for the presence of epithelial cells. Any contaminating fibroblasts were removed. We extracted DNA from the resulting breast and lung cancer cell lines at low, ...
4. Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Wallace K, Schildkraut JM. Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in African American women: A study of PD-L1 and IDO in 112 cases from the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol. 2018 Feb 26 [Epub ahead of print]. IF: 1.5 Role: Subject recruitment, data analysis, manuscript preparation. 5. Holowatyj AN*, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS. Racial differences in 21-Gene recurrence scores among patients with hormone receptor-positive, node-negative breast cancer. J Clin Oncol. 2018 Mar 1; 36(7):652-658. IF: 24.0. 6. Peres LC, Risch H, Terry KL, Webb PM, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, ...
Faculty contributors to the definition and algorithm:. Drs. R. Vang, R.J. Kurman, K. Visvanathan, P. Shaw, R. Soslow, V. Parkash, and I. Shih. The intention of the information provided in this web site is at present for educational and research purposes only. The biological and clinical significance of STIC and STIL is a work in progress and their impact to clinical management has still to be defined. The investigators involved in this study and all the web pages in ovariancancerprevention.org do not recommend the use of this pathological and immunostaining classification for clinical practice at the present time. Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecologic malignancy and is characterized by frequent TP53 mutations and a high level of chromosomal instability, which is reflected by widespread DNA copy number changes compared to other types of epithelial ovarian carcinomas. Unlike cancers arising in the colon, breast, cervix, endometrium, prostate, and pancreas, for ...
of the uterus, adenexae, onsectonomy and appendectomy for papillary serous carcinoma of the ovary . After 6 chemotherapy cycles tumor recurrence .... ...
Bouchalova, P., Nenutil, R., Muller, P., Hrstka, R., Appleyard, M. V., Murray, K., Jordan, L. B., Purdie, C. A., Quinlan, P., Thompson, A. M., Vojtesek, B. & Coates, P. J. Jul 2014 In : Journal of Pathology. 233, 3, p. 238-246 9 p.. Research output: Contribution to journal › Article ...
Patients with ovarian high-grade serous carcinoma (HGSC) initially respond to treatment with the chemotherapeutic agents carboplatin and paclitaxel, but frequently experience tumor relapse. However, the mechanisms underlying the development of resistance to these drugs remain poorly understood. Yu and colleagues found that the levels of spleen tyrosine kinase (SYK) and phosphorylated SYK were increased in recurrent ovarian tumors isolated from patients previously treated with carboplatin and paclitaxel compared with matched primary untreated tumors. In addition, SYK expression and activation were upregulated in paclitaxel-resistant ovarian cancer cell lines and positively correlated with paclitaxel response in vitro, suggesting that SYK overexpression may confer chemoresistance. SYK inactivation via knockdown or pharmacologic inhibition with the active metabolite of fostamatinib, R406, impaired the growth of ovarian cancer cells and synergistically enhanced the sensitivity of ...
The present review showed that IRT alone may be an adequate RT technique in women with stage I USC, who underwent appropriate surgical staging and received adjuvant chemotherapy.. Uterine serous carcinoma patients have a high-risk to develop local and distant relapse [28], therefore it is essential to ensure an adequate treatment even if patients with an early stage disease. While prospective studies have demonstrated that the delivery of chemotherapy in combination with external beam radiation in an advanced stage disease may increase survival benefit and decreases local recurrences [29,30,31,32,33], the role of radiation in early stage USC has been more difficult to demonstrate.. Owing to high-rate of distant recurrences, many studies recommended a more systemic approach to therapy for USC [34]. Treatment of women with uterine-confined USC with adjuvant chemotherapy is controversial due to lack of prospective randomized trials. However, in patients with stage I/II disease who were treated with ...
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
Brain Development The shaky pattern continues to knowledgeable everywhere early, and the developing in ceo circumference is indicative of wit growth. Shifting Responsibilities From Hospital-Based to Community-Based Nursing Care Over the sometime century changes in vigorousness attention, such as uncomfortable salubrity care funding, shorter asylum stays, and sell for containment, include led to a make it in responsibilities of care payment children from the infirmary to homes and communities. Chemic toxins are each approximately you in cleansing supplies, pesticides, herbicides, and matter additives generic 30 gm himcolin with mastercard natural erectile dysfunction treatment remedies. Patterns of p53 mutations partition ovarian serous borderline tumors and low- and high-grade carcinomas and provide keep proper for a new prototype of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Non-critical stimulation coupled effects (viscerosensory symptoms, cough, ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
One subtype of breast cancer shares many genetic features with high-grade serous ovarian cancer, a cancer that is very difficult to treat, according to researchers supported by the National Institutes of Health. The findings suggest that the two cancers are of similar molecular origin, which may facilitate the comparison of therapeutic data for subtypes of breast and ovarian cancers.
Decreased Expression of 14-3-3,i,σ,/i, Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma (2013 ...
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer - NCT04092270
Siddhartha P. Kar, Jonathan P. Tyrer, Qiyuan Li, Kate Lawrenson, Katja K.H. Aben, Hoda Anton-Culver, Natalia Antonenkova, Georgia Chenevix-Trench, ; on behalf of the Australian Cancer Study, ; and on behalf of the Australian Ovarian Cancer Study Group, Helen Baker, Elisa V. Bandera, Yukie T. Bean, Matthias W. Beckmann, Andrew Berchuck, Maria Bisogna, Line Bjørge, Natalia Bogdanova, Louise Brinton, Angela Brooks-Wilson, Ralf Butzow, Ian Campbell, Karen Carty, Jenny Chang-Claude, Yian Ann Chen, Zhihua Chen, Linda S. Cook, Daniel Cramer, Julie M. Cunningham, Cezary Cybulski, Agnieszka Dansonka-Mieszkowska, Joe Dennis, Ed Dicks, Jennifer A. Doherty, Thilo Dörk, Andreas du Bois, Matthias Dürst, Diana Eccles, Douglas F. Easton, Robert P. Edwards, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Yu-Tang Gao, Aleksandra Gentry-Maharaj, Graham G. Giles, Rosalind Glasspool, Ellen L. Goode, Marc T. Goodman, Jacek Grownwald, Patricia Harrington, Philipp Harter, Alexander Hein, Florian Heitz, Michelle ...
My name is Shirley Pattan, I live in Jacksonville, Florida with my spouse, two (of five!) kids, and three fur babies. I was diagnosed at 40 July 2017 with stage 3c high grade serous ovarian cancer, which prompted testing for the BRCA mutation.
Atıf İçin Kopyala Unal I., Khiavi I., Tasar G., Goksuluk D. , Boyraz G., Ozgul N., ...Daha Fazla Biotechnic & histochemistry : official publication of the Biological Stain Commission, ss.1-10, 2019 (SCI İndekslerine Giren Dergi) ...
It includes serous tumor, endometrioid tumor, and mucinous cystadenocarcinoma. Less common tumors are malignant Endometrioid ... Serous carcinomas are thought to begin in the Fallopian tube. Histologically, serous adenocarcinomas have psammoma bodies. Low- ... Serous carcinomas may develop from serous tubal intraepithelial carcinoma, rather than developing spontaneously from ovarian ... Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to ...
... ovarian cancer cell line derived from the ascites of a 64-year-old Caucasian female with an ovarian serous cystadenocarcinoma. ...
... cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.200.025.540 - ... cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.590.485 - cystadenoma ... cystadenocarcinoma MeSH C04.557.470.200.025.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 - ... cystadenocarcinoma MeSH C04.557.470.590.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.590.480.230 - ...
... mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma Acinar cell ...
NOS Serous cystoma Serous microcystic adenoma M8441/3 Serous cystadenocarcinoma, NOS (C56.9) Serous adenocarcinoma, NOS Serous ... M8460/0 Papillary serous cystadenoma, NOS (C56.9) M8460/3 Papillary serous cystadenocarcinoma (C56.9) Papillary serous ... Serous cystadenofibroma of borderline malignancy M9014/3 Serous adenocarcinofibroma Malignant serous adenofibroma Serous ... M8461/3 Serous surface papillary carcinoma (C56.9) Primary serous papillary carcinoma of peritoneum (C48.1) M8462/1 Serous ...
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Two tumor types were explored during the pilot phase, Glioblastoma Multiforma (GBM) and Cystadenocarcinoma of the Ovary. The ... TCGA reported on the exome sequencing of 316 tumor samples of high grade serous ovarian cancer in Nature in June 2011. TCGA ...
... is a type of tumor in the cystadenocarcinoma grouping. Most commonly, the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-7. doi:10.1097/01 ... 13(10):1864-8 (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Cite journal ... with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous ...
"Ovarian serous cystadenocarcinoma , Radiology Reference Article , Radiopaedia.org". Radiopaedia. Retrieved 2019-09-21. v t e v ... Serous ovarian cystadenocarcinomas account for ~25% of serous tumours. Ovarian cancer Pancreatic serous cystadenoma Serous ... also called serous borderline tumours, that may transform into serous carcinoma. Serous cystadenomas (of the ovary) are not ... Ovarian serous cystadenoma, also (less precisely) known as serous cystadenoma, is the most common ovarian neoplasm, ...
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. Papillary serous cystadenoma Kosary, ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ...
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... renal cell carcinoma Micropapillary subtype of lung adenocarcinoma Ovarian papillary serous cystadenoma and cystadenocarcinoma ... Endometrial adenocarcinomas (Papillary serous carcinoma ~3%-4%) Meningiomas, in the central nervous system Peritoneal and ...
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Serous cystadenocarcinoma Canada: Pancreatic Cancer - Ductal adenocarcinoma and Prostate Cancer - Adenocarcinoma China: Gastric ...
Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, ... "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J Gastrointest Surg. 13 (10): 1864-8. doi: ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. Similar tumor ...
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
卵巢浆液性囊腺瘤 / Pancreatic serous cystadenoma(英语:Pancreatic serous cystadenoma) / Serous cystadenocarcinoma(英语:Serous ... 粘液性囊腺瘤 / Mucinous cystadenocarcinoma(英语:Mucinous cystadenocarcinoma) *Pseudomyxoma peritonei(英语:Pseudomyxoma peritonei) ... 囊性肿瘤: 浆液性微
Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. Most commonly, the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-7. doi:10.1097/01 ... 13(10):1864-8 (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Cite journal ... with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous ...
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. Papillary serous cystadenoma Kosary, ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ...
Gastric metastasis from ovarian serous cystadenocarcinoma is extremely rare. Case presentation: We herein report one case of a ... Gastric metastasis of ovarian serous cystadenocarcinoma Shiqiang Yang Xintai Hospital Affiliated to Taishan Medical University ... Background: Gastric metastasis from ovarian serous cystadenocarcinoma is extremely rare.. Case presentation: We herein report ...
Ovarian Histopathology - Serous Cyst Adenocarcinoma. BACK TO VIDEOS Ovarian Histopathology - Serous Cyst Adenocarcinoma. ...
Serous papillary cystadenocarcinoma of the ovary. Last updated on May 10, 2019 at 16:47 ...
Serous cystic neoplasms of the pancreas carry a realistic risk of malignancy despite the general view that they never become ... In our opinion the treatment strategy of serous cystic neoplasms of the pancreas should be aggressive even in cases of remote ... A 86-year old patient known to have a serous cystadenoma of the pancreas treated conservatively through a close clinical and ... Serous adenomas represent 1-2% of pancreatic neoplasms and typically are asymptomatic not requiring any treatment and simple ...
Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade ... Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of ... Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade ...
... papillary serous cystadenocarcinoma was found to be associated with ovarian and skin malignancies and with myeloma; and ... risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. ... Associations were found between endometrioid carcinoma and endometrial malignancy and between serous carcinoma and Hodgkin ...
Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, ... "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J Gastrointest Surg. 13 (10): 1864-8. doi: ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. Similar tumor ...
Cystadenocarcinoma. Fallopian Tube Neoplasms. Carcinoma, Endometrioid. Cystadenocarcinoma, Serous. Cystadenocarcinoma, Mucinous ... Ovarian Mucinous Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Primary Peritoneal Carcinoma Recurrent Ovarian Carcinoma ... Fallopian Tube Carcinoma Malignant Ovarian Mixed Epithelial Tumor Ovarian Brenner Tumor Ovarian Clear Cell Cystadenocarcinoma ... Neoplasms, Cystic, Mucinous, and Serous. Fallopian Tube Diseases. Endometrial Neoplasms. Uterine Neoplasms. Neoplasms, ...
Cystadenocarcinoma, Serous. Adenocarcinoma, Mucinous. Cystadenocarcinoma. Brenner Tumor. Neoplasms, Glandular and Epithelial. ... Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Primary Peritoneal Serous Adenocarcinoma Stage IIA Fallopian ... Patients with the following histologic epithelial cell types are eligible: serous, endometrioid, clear cell, mucinous ... including papillary serous, clear cell or other FIGO grade 3 lesions ...
Cystadenocarcinoma, Serous. Adenocarcinoma, Mucinous. Cystadenocarcinoma. Adenocarcinoma, Clear Cell. Neoplasms by Histologic ... Ovarian Serous Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian ... Participant may have serous, endometrioid, clear cell, mucinous or undifferentiated type of recurrent epithelial ovarian, ... Neoplasms, Cystic, Mucinous, and Serous. Bevacizumab. Pembrolizumab. Cyclophosphamide. Endothelial Growth Factors. Antibodies. ...
... ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate ...
Cystadenocarcinoma. Neoplasms, Cystic, Mucinous, and Serous. Neoplasms, Complex and Mixed. Neoplasms, Connective and Soft ... Cystadenocarcinoma, Serous. Carcinosarcoma. Mixed Tumor, Mullerian. Adenocarcinoma, Clear Cell. Carcinoma. Neoplasms, Glandular ... Endometrial Clear Cell Adenocarcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Serous Adenocarcinoma Stage I Uterine ... Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the ...
... ovarian serous cystadenocarcinoma, n=430; SKCM: skin cutaneous melanoma, n=473; SARC: sarcoma, n=265; BRCA: breast invasive ...
Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. Ha M, Kim J, Park SM, Hong CM, Han ME, Song P, ... A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma Wenna ... A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma Wenna ... Results: The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas ( ...
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen.. Cho W, Cho YB, Jang KT, Kim HC, Yun SH, ... Pancreatic serous cystadenocarcinoma: a case report and review of the literature.. King JC, Ng TT, White SC, Cortina G, Reber ... Serous cystadenocarcinoma of the pancreas with portal thrombosis.. Vadalà S, Calderera G, Cinardi N, Manusia M, Li Volti G, ... A rare case of serous cystadenocarcinoma of the pancreas.. Yoshimi N, Sugie S, Tanaka T, Aijin W, Bunai Y, Tatematsu A, Okada T ...
4Mucinous cystadenocarcinoma. 5Serous cystadenocarcinoma. 6Darby canine kidney cells.. Table 2 ...
Cystadenocarcinoma, Serous / complications* * Cystadenocarcinoma, Serous / immunology * Cystadenocarcinoma, Serous / metabolism ...
Ovarian serous cystadenocarcinoma. Ns. Ns. [20]. 44, M. 3 months (symptoms carcinomatosis). Diplopia. Headache, confusion, ...
... ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate ...
... ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; SARC, sarcoma; STAD, stomach ...
Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases ... Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of ... Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases ... Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases ...
In the present study, a case of isolated small intestine metastasis of ovarian papillary cystadenocarcinoma was reported. A 7- ... this is the first case of small intestine serousal surface metastasis from ovarian papillary cystadenocarcinoma. ... Ovarian cystadenocarcinoma is characterized by marked heterogeneity and may be composed of an admixture of histologic growth ... features coupled with the CK7 immunoreactivity led to a diagnosis of high grade ovarian papillary cystadenocarcinoma. To the ...
... and mutations of EGFR and ERBB2 in serous carcinoma, the most common and aggressive type of ovarian cancer. … ... Cystadenocarcinoma, Serous / genetics* * Cystadenocarcinoma, Serous / metabolism * Cystadenocarcinoma, Serous / mortality * ... Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med (Berl ... Both amplification and protein overexpression of EGFR occur in serous ovarian carcinoma, but EGFR copy number has a stronger ...
Ovarian serous cystadenocarcinoma. 20 %. FGFR1 5 %FGFR3 8 %. FGFR2 4 %FGFR4 4 % ...
Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and Paraganglioma; PRAD, Prostate ...
BRCA, breast invasive carcinoma; OV, ovarian serous cystadenocarcinoma; UCEC, uterine corpus endometrial carcinoma; LUSC, lung ...
  • Serous Microcystic Adenocarcinoma of Pancreas Infiltrating Into Spleen: A Case Report. (nih.gov)
  • Ovarian cancer is thought to arise from neoplastic changes that result in the pathologic differentiation of OSE into the established histologic subtypes, which include serous (fallopian tube-like), endometrioid (endometrium-like), and mucinous (endocervical-like) adenocarcinoma among others. (aacrjournals.org)
  • Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. (semanticscholar.org)
  • ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. (nih.gov)
  • There are four major histological subtypes in EOC, and serous adenocarcinoma and clear cell adenocarcinoma are high-grade malignancies. (nih.gov)
  • We therefore analyzed ovarian CSCs/CICs from ovarian carcinoma cell lines (serous adenocarcinoma and clear cell adenocarcinoma) and primary ovarian cancer cells in this study. (nih.gov)
  • Immunohistochemical staining revealed that higher ALDH1 expression levels in ovary cancer cases are related to poorer prognosis in both serous adenocarcinoma cases and clear cell adenocarcinoma cases. (nih.gov)
  • Left: Patient No.4, case of stage IIIc serous adenocarcinoma. (nih.gov)
  • Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? (amedeo.com)
  • Granulosa cell tumors, primary ovarian carcinoma such as mucinous and serous cystadenocarcinoma, and undifferentiated adenocarcinoma were the most prevalent malignant masses. (news-medical.net)
  • Women with endometriosis are at increased risk of developing ovarian cancer, specifically ovarian endometrioid, low-grade serous, and clear-cell adenocarcinoma. (mdpi.com)
  • The presence of endometriosis increases the risk of ovarian endometrioid, low-grade serous, and clear-cell adenocarcinoma by up to 8.9-fold but not high-grade serous adenocarcinoma [ 7 , 8 , 9 , 10 , 11 , 12 ]. (mdpi.com)
  • Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. (wikipedia.org)
  • Further imaging-based characterization of the possible histopathology of lesion may help in differentiating a benign pseudocyst from a cystic tumor of the pancreas, a mucinous cystic tumor from a serous tumor, and a neuroendocrine tumor from other solid neoplasias may help in determination of resectability of each of these pancreatic lesions. (springer.com)
  • Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian tumours in women aged over 20 in the United States. (wikipedia.org)
  • Serous cystic neoplasms of the pancreas carry a realistic risk of malignancy despite the general view that they never become malignant. (biomedcentral.com)
  • Also called glycogen-rich cystadenoma or microcystic adenoma is generally considered to be a benign condition although serous cystadenocarcinoma is a rare but known malignant condition described in the literature. (biomedcentral.com)
  • Most of these are benign (serous cystadenomas), and in rare cases are malignant (serous cystadenocarcinoma). (biomedcentral.com)
  • In 1989, George et al [ 8 ] first reported a case of serous microcystic adenoma behaving in a malignant fashion and since then, according to our best knowledge, 26 cases have been reported in the literature. (biomedcentral.com)
  • Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. (wikipedia.org)
  • Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature. (nih.gov)
  • Amongst benign tumors, serous cystadenoma was the most frequent subtype, while for the malignant tumors serous cystadenocarcinoma was the commonest. (thefreelibrary.com)
  • Grade 3, Stage Iiic, Malignant Papillary Serous Adenocarcino. (atcc.org)
  • Cystadenocarcinoma ( papillary cystadenocarcinoma ) of the salivary gland is a rare malignant neoplasm. (labome.org)
  • This study analyzes the clinicopathologic and radiologic characteristics of malignant serous cystic neoplasm (SCN) of the pancreas through systematic review and an institutional case report. (biomedcentral.com)
  • classified cystic neoplasms of the pancreas into serous and mucinous types in 1978 [ 6 ], SCNs were considered as a benign disease entity without risk of malignant transformation. (biomedcentral.com)
  • Rare occurrence in the pancreas has been reported, although this is not typical, with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous cystadenoma. (wikipedia.org)
  • A 86-year old patient known to have a serous cystadenoma of the pancreas treated conservatively through a close clinical and radiological follow up which was unattended for 4 years ending up to our emergency department suffering an acute abdomen. (biomedcentral.com)
  • Risk of malignancy in serous cystic neoplasms of the pancreas. (nih.gov)
  • Serous cystadenocarcinoma of the pancreas with portal thrombosis. (nih.gov)
  • Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. (semanticscholar.org)
  • According to the latest WHO classification these tumors are called serous cystic neoplasms, which are cystic epithelial neoplasms composed of glycogen-rich, epithelial cells that produce a watery fluid similar to serum. (biomedcentral.com)
  • Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer University School of Medicine. (wikipedia.org)
  • By sequencing peritoneal fluid from women with high-grade serous ovarian cancer, we demonstrate that duplex sequencing, currently the most accurate sequencing technology, is able to detect one cancer cell among tens of thousands of normal cells. (pnas.org)
  • Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. (wikipedia.org)
  • About 25% of adnexal growths are endometriomas, 33% are mature cystic teratomas, and the rest are functional cysts or serous or mucinous cystadenomas. (news-medical.net)
  • Ovarian cystadenocarcinoma is characterized by marked heterogeneity and may be composed of an admixture of histologic growth patterns, including acinar, papillary and solid. (biomedcentral.com)
  • She underwent a liver resection, and histopathology confirmed a serous biliary cystadenoma. (uwi.edu)
  • Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (wikipedia.org)
  • We isolated ovarian CSCs/CICs as an aldehyde dehydrogenase 1 high (ALDH1(high)) population from 6 EOC cell lines (3 serous adenocarcinomas and 3 clear cell adenocarcinomas) by the ALDEFLUOR assay. (nih.gov)
  • Thus, ovarian endometrioid, low-grade serous, and clear-cell adenocarcinomas are considered endometriosis-associated ovarian cancers. (mdpi.com)
  • The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. (cdc.gov)
  • Immunohistochemical and ultrastructural findings in a rare case of papillary cystadenocarcinoma arising from the left sublingual gland of a 55-year-old Japanese man are reported. (labome.org)
  • Genomic complexity and AKT dependence in serous ovarian cancer. (harvard.edu)
  • Patients must have newly diagnosed, stage II-IV low-grade serous ovarian cancer (submission of pathology report[s] required). (uccancer.org)
  • If aberrant p53 expression is found on p53 IHC, the patient is NOT eligible (aberrant p53 expression is consistent with mutant TP53 and supports diagnosis of high grade serous ovarian cancer). (uccancer.org)
  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? (duke.edu)
  • OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. (duke.edu)